Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
Completion of preclinical studies support potential to advance PXL770 into Phase 2 development for ADPKD
Compelling preclinical efficacy data confirm strategic focus for PXL770 in rare metabolic diseases
LYON, France--...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | France Health | Pharmaceuticals | Polycystic Kidney Disease | Study | Urology & Nephrology